Prevalence of Osteoporosis in Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

142 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-18

Study Completion Date

2021-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.

This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus

NCT00582465

Lupus Erythematosus, Systemic

COMPLETED

Prevalence of Musculoskeletal Disorders of Upper Limb in Type 1 Diabetes Patients

NCT05164562

Type 1 Diabetes

UNKNOWN

Awareness of Osteoporosis in Ankylosing Spondylosis Patients

NCT05760105

Osteoporosis Osteoporosis Risk Ankylosing Spondylitis

UNKNOWN

Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta

NCT04119388

Osteogenesis Imperfecta

COMPLETED NA

Genzyme Osteopenia/Osteoporosis Study

NCT02785744

Gaucher Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sickle cell disease patients

150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study

Questionnaire

Intervention Type OTHER

For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Black-skinned men and women
* Aged 20 to 40 years old
* Sickle cell patients
* Non-opposition to participate in the study

Exclusion Criteria

* Refusal to participate in the study
* Hemoglobinopathy other than sickle cell disease
* Severe or End Stage Renal Failure
* Long-term corticosteroid therapy (\>3 months)
* History of solid cancer or malignant haemopathy
* History of organ transplantation
* Pregnant or breastfeeding woman
* Psychiatric pathology seriously impeding understanding
* Difficulty understanding oral French

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No